The NHS has reported treating its first patient with Novartis’ Luxturna (voretigene neparvovec), which has been heralded as a “revolutionary” new gene therapy that can restore eyesight and is featured as part of its NHS Long Term Plan. The therapy is available for those born with an inherited retinal disorder (Leber’s Congenital Amaurosis, where patients
Sandoz, a division of Swiss pharma giant Novartis, reveals that two of its biosimilars: Rixathon (biosimilar rituximab) and Erelzi (biosimilar etanercept) are now available in the UK for use in Europe. Both new medicines have proven to be non-inferior to their reference products, MabThera and Enbrel, respectively. Both products are approved in all the same
Novartis has entered a clinical research collaboration with Bristol-Myers Squibb to investigate the safety, tolerability, and efficacy of Mekinist in combination with Opdivo and Opdivo + Yervoy regimen. The cancer treatments are being used as a potential option for metastatic colorectal cancer in patients with microsatellite stable tumours where the tumours are proficient in mismatch
Novartis yesterday confirmed that they will be closing all operations at their Horsham site later this year, putting nearly 400 jobs at risk. The Swiss pharmaceutical organisation initially announced in November that they were considering the site’s closure as part of their global review of R&D locations. Following from the announcement, Novartis has now confirmed
